Hospira Vinorelbine Tartrate 50 mg/5 mL Injection vial

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

vinorelbine tartrate, Quantity: 13.85 mg/mL

Verfügbar ab:

Hospira Australia Pty Ltd

INN (Internationale Bezeichnung):

Vinorelbine tartrate

Darreichungsform:

Injection

Zusammensetzung:

Excipient Ingredients: water for injections

Verabreichungsweg:

Intravenous

Einheiten im Paket:

1 X 5 mL

Klasse:

Medicine Listed (Export Only)

Verschreibungstyp:

Not scheduled. Not considered by committee

Anwendungsgebiete:

Vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC). In patients with Stage IV NSCLC, Vinorelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, Vinorelbine is indicated in combination with cisplatin.

Produktbesonderheiten:

Visual Identification: A clear, colourless to pale yellow solution & free from visible particulates; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Berechtigungsstatus:

Licence status A

Berechtigungsdatum:

2008-05-21